Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: $260.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 01, 2020
Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.
Lead Product(s): Sulcardine sulfate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation.